CLB Stock Analysis: Core Laboratories | NYSE
Oil & Gas Equipment & Services | NYSE, USA | Market Cap: 474m USD | 12M Return: -36.1% | US21867A1051 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 6.40M
EPS Trend: -71.8%
Qual. Beats: 1
Rev. Trend: 53.7%
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Core Laboratories Inc. (NYSE: CLB) is a Houston-based provider of reservoir description and production enhancement services to the oil and gas industry, operating in the United States and internationally. Founded in 1936, the company runs two segments: Reservoir Description, which analyzes rock and fluid samples to optimize hydrocarbon recovery and supports adjacent applications such as carbon capture, utilization and storage (CCUS), geothermal energy, and mining evaluation; and Production Enhancement, which delivers diagnostic services and products for well completions, perforations, stimulations, production, and well abandonment. Sales channels include direct representatives, technical seminars, trade shows, print advertising, and third-party distributors.
CLB sits within the Energy sectors Oil & Gas Equipment & Services sub-industry, meaning its revenue is tied to upstream exploration and production activity rather than commodity prices. As a specialized oilfield services and laboratory analytics provider, it depends on operators capital and operating budgets, which historically are cyclical and sensitive to crude oil and natural gas prices. The companys expansion into CCUS and geothermal reflects a broader diversification trend among oilfield services firms seeking exposure to energy transition segments that also rely on subsurface reservoir expertise.
- Middle East and Latin America activity lifts international segment revenue
- CCUS and geothermal diversification offset US shale weakness
- Share buybacks and dividends sustain capital returns through cyclical downturn
| Net Income: 15.6m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.04 > 0.02 and ΔFCF/TA -2.29 > 1.0 |
| NWC/Revenue: 23.67% < 20% (prev 25.35%; Δ -1.67% < -1%) |
| CFO/TA 0.04 > 3% & CFO 24.7m > Net Income 15.6m |
| Net Debt (151.6m) to EBITDA (53.9m): 2.81 < 3 |
| Current Ratio: 2.19 > 1.5 & < 3 |
| Outstanding Shares: last quarter (46.7m) vs 12m ago -0.78% < -2% |
| Gross Margin: 16.35% > 18% (prev 17.12%; Δ -0.77% > 0.5%) |
| Asset Turnover: 87.22% > 50% (prev 87.51%; Δ -0.29% > 0%) |
| Interest Coverage Ratio: 3.50 > 6 (EBIT TTM 38.9m / Interest Expense TTM 11.1m) |
| A: 0.21 (Total Current Assets 225.1m - Total Current Liabilities 102.7m) / Total Assets 593.5m |
| B: 0.29 (Retained Earnings 172.7m / Total Assets 593.5m) |
| C: 0.07 (EBIT TTM 38.9m / Avg Total Assets 592.4m) |
| D: 0.92 (Book Value of Equity 284.1m / Total Liabilities 309.4m) |
| Altman-Z'' = 3.71 = AA |
| DSRI: 0.93 (Receivables 115.6m/125.0m, Revenue 516.7m/517.5m) |
| GMI: 1.05 (GM 17.12% / 16.35%) |
| AQI: 0.96 (AQ_t 0.34 / AQ_t-1 0.36) |
| SGI: 1.00 (Revenue 516.7m / 517.5m) |
| TATA: -0.02 (NI 15.6m - CFO 24.7m) / TA 593.5m) |
| Beneish M = -3.07 (Cap -4..+1) = AA |
As of October 29, 2026, the stock is trading at USD 10.49 with a total of 976,970 shares traded. Over the past week, the price has changed by +3.55%, over one month by +4.59%, over three months by -1.78% and over the past year by -36.13%.
Current recommended Stop Loss: 9.90 (which is 5.6% or 1.4 ATR below the current price).
Core Laboratories has received a consensus analysts rating of 3.67. Therefore, it is recommended to hold CLB.
- StrongBuy: 1
- Buy: 1
- Hold: 0
- Sell: 1
- StrongSell: 0
| Analysts Target Price | 15 | 43% |
P/E Trailing = 19.4906
P/E Forward = 19.7628
P/S = 0.913
P/B = 1.7198
P/EG = 1.6717
Revenue TTM = 516.7m USD
EBIT TTM = 38.9m USD
EBITDA TTM = 53.9m USD
Long Term Debt = 110.3m USD (from longTermDebt, last fiscal year)
Short Term Debt = 11.5m USD (from shortTermDebt, last fiscal year)
Debt = 173.0m USD (corrected: LT Debt 110.3m + ST Debt 11.5m) + Leases 51.3m
Net Debt = 151.6m USD (calculated: Debt 173.0m - CCE 21.4m)
Enterprise Value = 625.6m USD (474.0m + Debt 173.0m - CCE 21.4m)
Interest Coverage Ratio = 3.50 (Ebit TTM 38.9m / Interest Expense TTM 11.1m)
EV/FCF = 29.95x (Enterprise Value 625.6m / FCF TTM 20.9m)
FCF Yield = 3.34% (FCF TTM 20.9m / Enterprise Value 625.6m)
FCF Margin = 4.04% (FCF TTM 20.9m / Revenue TTM 516.7m)
Net Margin = 3.01% (Net Income TTM 15.6m / Revenue TTM 516.7m)
Gross Margin = 16.35% ((Revenue TTM 516.7m - Cost of Revenue TTM 432.2m) / Revenue TTM)
Gross Margin QoQ = none% (prev 18.65%)
Tobins Q-Ratio = 1.05 (Enterprise Value 625.6m / Total Assets 593.5m)
Interest Expense / Debt = 6.44% (Interest Expense 11.1m / Debt 173.0m)
Taxrate = 43.76% (12.2m / 27.8m)
NOPAT = 21.9m (EBIT 38.9m * (1 - 43.76%))
Current Ratio = 2.19 (Total Current Assets 225.1m / Total Current Liabilities 102.7m)
Debt / Equity = 0.61 (Debt 173.0m / totalStockholderEquity, last quarter 284.1m)
Debt / EBITDA = 2.81 (Net Debt 151.6m / EBITDA 53.9m)
Debt / FCF = 7.26 (Net Debt 151.6m / FCF TTM 20.9m)
Total Stockholder Equity = 272.9m (last 4 quarters mean from totalStockholderEquity)
RoA = 2.63% (Net Income 15.6m / Total Assets 593.5m)
RoE = 5.70% (Net Income TTM 15.6m / Total Stockholder Equity 272.9m)
RoCE = 10.16% (EBIT 38.9m / Capital Employed (Equity 272.9m + L.T.Debt 110.3m))
RoIC = 4.55% (NOPAT 21.9m / Invested Capital 480.9m)
WACC = 7.81% (E(474.0m)/V(647.0m) * Re(9.34%) + D(173.0m)/V(647.0m) * Rd(6.44%) * (1-Tc(0.44)))
Discount Rate = 9.34% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -77.99 | Cagr: -0.97%
[DCF] Terminal Value 73.10% ; FCFF base≈26.3m ; Y1≈23.1m ; Y5≈18.6m
[DCF] Fair Price = 3.21 (EV 298.9m - Net Debt 151.6m = Equity 147.3m / Shares 45.9m; r=8.35% [WACC [floored]]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: -71.75 | EPS CAGR: -8.06% | SUE: 1.20 | # QB: 1
Revenue Correlation: 53.68 | Revenue CAGR: 0.61% | SUE: -0.02 | # QB: 0
EPS current Quarter (2026-09-30): EPS=0.16 | Chg30d=+4.37% | Revisions=+25% | Analysts=3
EPS current Year (2026-12-31): EPS=0.51 | Chg30d=+10.95% | Revisions=+25% | GrowthEPS=-32.4% | GrowthRev=-2.8%
EPS next Year (2027-12-31): EPS=0.69 | Chg30d=-1.89% | Revisions=-25% | GrowthEPS=+36.2% | GrowthRev=+2.5%
[Analyst] Revisions Ratio: +17% (up=2, down=1)